이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

HFpEF 환자에서 우측 대 내장 신경의 혈관내 절제술 (Rebalance-HF)

2026년 9월 16일 업데이트: Axon Therapies, Inc.

HFpEF 환자에서 우측 대 내장 신경의 혈관내 절제술에서 우측 대 내장 신경의 혈관내 절제술: 타당성 연구: 무작위 통제 타당성 시험 재조정 HF 연구

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

연구 개요

상세 설명

Up to 150 people will take part in this clinical study.

Phase I of the REBALANCE-HF Study

The first part of the study took place between January 2021 and March 2023. During this phase, 116 patients participated. Researchers reviewed the results to learn whether the procedure appeared safe and whether it might help improve symptoms in people with heart failure with preserved ejection fraction (HFpEF).

This early review showed encouraging results in some patients. It also helped researchers identify a group of patients who seemed more likely to benefit from the procedure.

Phase II of the REBALANCE-HF Study:

The current phase of the study focuses on patients who have similar characteristics to those who responded well in Phase I. The goal is to confirm whether this group of patients may benefit most from the treatment and whether the procedure should be studied further in a larger future trial.

This study will take place at multiple hospitals and research centers.

Participants who qualify for the study will be randomly assigned to one of two groups:

  • Treatment group: The procedure is performed using the Satera Ablation System to treat a nerve called the greater splanchnic nerve.
  • Control (sham) group: A simulated procedure is performed, but the treatment itself is not delivered.

Participants will be assigned to a group by chance, similar to flipping a coin, although twice as many patients will receive the treatment as the sham procedure (2:1 ratio).

The group assignment will happen during the procedure after anesthesia is given, and only after the doctor confirms that the patient's anatomy is suitable for the procedure.

Blinding:

To make sure the results are fair and unbiased:

  • Participants and their heart failure doctors will not know whether the patient received the treatment or the sham procedure.
  • The doctor performing the procedure and certain study staff will know which procedure is performed so they can carry out the procedure safely.
  • The study safety team will also know this information to help monitor patient safety.

Sham Procedure:

A sham procedure is used to help researchers understand whether any improvements are due to the treatment itself or to the placebo effect.

During the sham procedure:

A small needle puncture is made in the groin or neck, similar to what is done for many heart procedures.

Doctors check the veins to confirm whether the procedure could have been performed.

However, the treatment catheter is not used and the nerve is not treated.

The sham procedure takes about 45 minutes, which is about the same amount of time as the treatment procedure.

Number of Participants:

90 patients were assigned to treatment or sham during Phase I.

In Phase II, up to 60 additional patients will be enrolled.

About 40 patients will receive the treatment, and about 20 will receive the sham procedure.

연구 유형

중재적

등록 (추정된)

150

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Tbilisi, 그루지야
        • 모병
        • Tbilisi Heart and Vascular Center
        • 수석 연구원:
          • Tamaz Shaburishvili, MD
        • 연락하다:
      • Tbilisi, 그루지야
        • 모집하지 않고 적극적으로
        • Tbilisi Heart Center
    • Alabama
      • Birmingham, Alabama, 미국, 35211
        • 완전한
        • Cardiology PC
    • Arizona
      • Phoenix, Arizona, 미국, 85016
        • 완전한
        • Arizona Cardiovascular Research Center
    • California
      • La Jolla, California, 미국, 92037
        • 모병
        • Scripps Health
        • 수석 연구원:
          • Rajeev Mohan, MD
        • 수석 연구원:
          • Matthew Price, MD
        • 연락하다:
      • San Francisco, California, 미국, 94143
        • 모병
        • University of California, San Francisco
        • 수석 연구원:
          • Liviu Klein, MD
        • 연락하다:
      • San Francisco, California, 미국, 94143
        • 모병
        • Zuckerberg San Francisco General Hospital and Trauma Center
        • 연락하다:
        • 수석 연구원:
          • Lucas ZIer, MD
    • Georgia
      • Augusta, Georgia, 미국, 30901
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Bluhm Cardiovascular Institute of Northwestern University
        • 수석 연구원:
          • Ravi Patel, MD
        • 연락하다:
      • Chicago, Illinois, 미국, 60637
      • Springfield, Illinois, 미국, 62701
        • 완전한
        • Prairie Education and Research Cooperative
    • Indiana
      • Indianapolis, Indiana, 미국, 46260
        • 완전한
        • Ascension St. Vincent - Cardiovascular Research Institute
    • Louisiana
      • Houma, Louisiana, 미국, 70360
        • 모병
        • Cardiovascular Institute of the South
        • 수석 연구원:
          • Peter Fail, MD
        • 연락하다:
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • Michigan Medicine, University of Michigan
        • 수석 연구원:
          • Scott Hummel, MD
        • 연락하다:
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic
        • 수석 연구원:
          • Barry Borlaug, MD
        • 연락하다:
    • Missouri
      • St Louis, Missouri, 미국, 63136
        • 모병
        • St. Louis Heart and Vascular
        • 수석 연구원:
          • Gil Vardi, MD
        • 연락하다:
    • New York
      • New York, New York, 미국, 10021
        • 모병
        • Weill Cornell Medicine
        • 수석 연구원:
          • Parag Goyal, MD
        • 연락하다:
      • New York, New York, 미국, 10032
        • 모병
        • Columbia University Medical Center
        • 수석 연구원:
          • Nir Uriel, MD
        • 연락하다:
      • New York, New York, 미국, 10029
        • 완전한
        • Icahn School of Medicine at Mount Sinai
      • Rochester, New York, 미국, 14621
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • 모병
        • Duke University Medical Center
        • 수석 연구원:
          • Marat Fudim, MD, MHS
        • 연락하다:
    • Ohio
      • Cincinnati, Ohio, 미국, 45219
        • 아직 모집하지 않음
        • The Christ Hospital
        • 수석 연구원:
          • Odayme Quesada, MD
        • 연락하다:
      • Columbus, Ohio, 미국, 43210
        • 모병
        • Ohio State University Wexner Medical Center
        • 수석 연구원:
          • Alexandria Miller, MD
        • 연락하다:
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 모병
        • Medical University of South Carolina
        • 수석 연구원:
          • Sheldon Litwin, MD
        • 연락하다:
    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • Baylor College of Medicine
        • 수석 연구원:
          • Ajith Nair, MD
        • 연락하다:
    • Virginia
      • Richmond, Virginia, 미국, 23298
        • 완전한
        • Virginia Commonwealth University Medical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  1. Chronic heart failure, defined as:

    1. Symptoms of HF requiring current (intermittent or continuous) treatment with diuretics for >30 days, AND
    2. NYHA class II with a history of >NYHA class II in the past year, NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening or signs of HF (any rales post cough, chest x-ray demonstrating pulmonary congestion), AND
    3. At least one of the following:

    i. ≥1 HF hospital admission (with HF as the primary diagnosis) including treatment with intravenous (IV) diuretics or urgent unplanned treatment with IV diuretics in healthcare facility within past 12 months, OR ii. NT-proBNP >300 pg/ml in normal sinus rhythm (>450 pg/ml in atrial fibrillation or flutter) within the past 6 months; BNP >100 pg/ml in normal sinus rhythm (>300 pg/ml in atrial fibrillation or flutter) within the past 6 months, OR iii. Right heart catheterization (RHC) with PCWP ≥ with PCWP ≥18 mmHg at rest or 25 mmHg during exercise at the time of the screening RHC.

  2. Ongoing stable GDMT HF management (unless unable to tolerate GDMT) and management of potential comorbidities according to the 2022 ACCF/AHA Guideline for the Management of Heart Failure (Class 1 and 2a recommendations), with no significant changes [≥100% increase or ≥50% decrease] for a minimum of 1 month (30 days) prior to screening, that is expected to be maintained without change for at least 6 months. Participants cannot have started a glucagon-like peptide (GLP)-1 or gastric inhibitory peptide (GIP) agonist within the last 6 months or plan to start a GLP-1 or GIP agonist within the ensuing 6 months after enrollment.

  3. LVEF ≥50% (site-determined by transthoracic echocardiography) within the past 6 months.

  4. Age ≥40 years.

  5. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.

Exclusion Criteria:

  1. MI (type I) and/or percutaneous cardiac intervention within 3 months prior to screening; CABG in past 3 months prior to screening, or current indication for coronary revascularization.

  2. Cardiac resynchronization therapy initiated within 3 months prior to screening.

  3. Advanced heart failure defined as one or more of the following:

    1. ACC/AHA/ESC Stage D HF or non-ambulatory NYHA Class IV HF.
    2. Inotropic infusion (continuous or intermittent) within 6 months prior to screening.
    3. Subject is on the cardiac transplant waiting list.
    4. Presence of or prior history of mechanical circulatory support for HF.
  4. Poor left heart compliance as determined by pulse-wave Doppler transmitral early-to-late (E/A) ratio >2.0 assessed by the screening echocardiogram. The Screening Committee will evaluate left heart function if the transmitral A velocity is not measurable or absent.

  5. Right heart dysfunction defined as tricuspid annular plane systolic excursion (TAPSE) <12 mm or right ventricular (RV) fractional area change (FAC) <25% assessed by the screening echocardiogram.

  6. Body mass index (BMI) >45 kg/m2.

  7. 6-minute walk test distance <100 meters OR >450 meters.

  8. Admission for HF within the 30 days prior to planned index procedure.

  9. Any known history of orthostatic hypotension or orthostatic hypotension at the time of screening (regardless of the presence of symptoms). Orthostatic hypotension is defined as a systolic blood pressure (BP) decrease of >20 mmHg upon going from supine to standing position or undergoing treatment with Midodrine.

  10. Orthostatic pulse pressure change from supine to standing decrease of >10mmHg in the absence of a HR increase >15bpm

  11. Postural orthostatic tachycardia syndrome or preload insufficiency syndrome.

  12. Systolic BP <100 mmHg or >170 mmHg despite appropriate medical management.

  13. Baseline screening ECG resting HR >100 beats per minute or ventricular tachycardia.

  14. Catheter ablation for atrial fibrillation within 6 months prior to screening or planned in the next 12 months at the time of screening.

  15. Left ventricular EF <40% within the 3 years prior to screening unless reduced EF was transient and associated with an acute event.

  16. Presence of significant valve disease defined by the site cardiologist as:

    1. Greater than mild mitral valve stenosis.
    2. Greater than moderate mitral valve regurgitation.
    3. Greater than moderate-to-severe tricuspid valve regurgitation.
    4. Greater than moderate aortic valve stenosis or regurgitation.
  17. Known hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis).

  18. History of clinically significant liver cirrhosis.

  19. Prior weight loss surgery

  20. Dialysis dependent; or estimated GFR <25 ml/min/1.73 m2 by CKD-EPI creatinine equation.

  21. Arterial oxygen saturation <90% on room air.

  22. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation of chronic pulmonary disease (including intubation) in the 12 months before study entry OR known history of GOLD Class III or worse chronic obstructive pulmonary disease (COPD).

  23. Participating in conflicting investigational drug or device study that is not completed within 30 days prior to the screening visit.

  24. Life expectancy <12 months for non-cardiovascular reasons.

  25. Any condition, or history of illness or surgery that, in the opinion of the site investigator or Screening Committee, might confound the results of the study or pose additional risks to the patient.

  26. Females who are pregnant or lactating or planning to become pregnant during the next year.

  27. Any of the following measured by screening right heart catheterization:

    1. Mean right atrial pressure (RAP) >20 mmHg at rest
    2. Cardiac index <2.0 L/min/m2 at rest
    3. Pulmonary vascular resistance (PVR) >4 Wood units

    Exclusion Criteria Assessed During the index procedure:

  28. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel. This includes previous spine surgery that may impact the ability to access and treat the target sites of T11 and T10.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Greater Splanchnic Nerve Ablation

After anesthesia is given, doctors will use the Satera Ablation System to reach a nerve called the right greater splanchnic nerve. Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.

The greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.

가짜 비교기: Sham Control Arm

After anesthesia is given, doctors will place a small tube into a vein. The steps and length of the procedure will be similar to the Axon treatment procedure, but the study treatment will not be performed.

During the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Primary Safety Endpoint: Device or procedure related serious adverse events
기간: 1 Month

Evaluation of device or procedure-related serious adverse events at 1-month follow-up based on Clinical Events Committee (CEC) assessment

1 Month
Primary Efficacy Endpoint: KCCQ (6 months)
기간: Baseline through 6-months

Assessment of change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 6-month follow up visit

Baseline through 6-months
Primary Efficacy Endpoint: 6MWT (6 months)
기간: Baseline through 6 months

Assessment of change in Six Minute Walk Test (6MWT) from baseline to the 6-month follow up visit

Baseline through 6 months

2차 결과 측정

결과 측정
측정값 설명
기간
Pulmonary Capillary Wedge Pressure (PCWP)
기간: Baseline through 1-month

Change in pulmonary capillary wedge pressure (PCWP) at resting, legs up, 20 Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit

Baseline through 1-month
Stress blood volume
기간: Baseline through 1-month

Change in estimated stress blood volume at resting, legs up, 20Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit.

Baseline through 1-month
NT-proBNP
기간: Baseline through 24-months

Change in NT-proBNP levels from Baseline through the 24-month visit

Baseline through 24-months
KCCQ (24-months)
기간: Baseline through 24-months

Change in KCCQ scores from baseline through the 24-month visit

Baseline through 24-months
6MWT (24-months)
기간: Baseline through 24-months

Change in 6MWT from Baseline through the 24-month visit

Baseline through 24-months
Time to first heart failure event
기간: Treatment through 24-months

Time to first heart failure event (hospitalizations and worsening heart failure events) through the 24-month visit

Treatment through 24-months
Incidence of heart failure events
기간: Treatment through 24-months

Incidence of heart failure events (hospitalizations and worsening heart failure events) through the 24-month visit

Treatment through 24-months
Hierarchical composite endpoint (12-months)
기간: Baseline through 12-months

Composite endpoint of cardiovascular death, heart failure events, and changes in KCCQ from Baseline to the 12-month visit

Baseline through 12-months
Incidence of serious device related cardiac or vascular events
기간: Treatment through 12- and 24-months

Assessment of the incidence of serious device related cardiac or vascular events through 12- and 24-months

Treatment through 12- and 24-months
Device or procedure related pain
기간: Treatment through 24-months

Assessment of device or procedure related pain lasting at least 30 days and requiring medical management

Treatment through 24-months
Orthostatic hypotension
기간: Treatment through 12- and 24-months

Incidence of new orthostatic hypotension up to 12- and 24-months

Treatment through 12- and 24-months
Acute Kidney Injury (AKI)
기간: Baseline through 12-and 24-months

Incidence of AKI requiring renal replacement therapy up to 12- and 24-months

Baseline through 12-and 24-months
Glomerular Filtration Rate (GFR)
기간: Baseline through 12- and 24-months

Incidence of worsening GFR (defined as >50% for at least 30 days in duration) up to 12- and 24-months

Baseline through 12- and 24-months
Adverse Events
기간: Procedure through 12- and 24-months

Incidence of all Adverse Events through 12- and 24-months

Procedure through 12- and 24-months
Mortality
기간: Procedure through 6-, 12- and 24-months

Incidence of all mortality for up to 6-, 12-, and 24-months summarized as all-cause mortality, CV mortality, or heart failure-related

Procedure through 6-, 12- and 24-months

기타 결과 측정

결과 측정
측정값 설명
기간
Exploratory endpoint: Heart failure related medication changes (24-months)
기간: Baseline through 24-months

Freedom from heart failure related medication changes through the 24-month visit

Baseline through 24-months
Exploratory Endpoint: Diuretic medication (24-months)
기간: Baseline through 24-months

Change in diuretic dose through the 24-month visit

Baseline through 24-months
Exploratory Endpoint: Diastolic function (24-months)
기간: Baseline through 24-months

Assessment of diastolic function by transthoracic echocardiography evaluated over time from baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: C-reactive protein
기간: Baseline through 24-months

Change in c-reactive protein levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Aldosterone (ALD)
기간: Baseline through 24-months

Change in aldosterone levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Renin
기간: Baseline through 24-months

Change in Renin levels from Baseline through 24-months

Baseline through 24-months
Exploratory Endpoint: Weight
기간: Baseline through 24-months

Change in weight from Baseline through 24-months

Baseline through 24-months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Sanjiv S Shah, MD, Northwestern University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 12월 18일

기본 완료 (추정된)

2028년 1월 10일

연구 완료 (추정된)

2029년 8월 10일

연구 등록 날짜

최초 제출

2020년 10월 7일

QC 기준을 충족하는 최초 제출

2020년 10월 13일

처음 게시됨 (실제)

2020년 10월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 16일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 09868

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다